缺氧诱导因子 2α、铁调素及其相互作用作为促进肿瘤发生的信号。
HIF2α, Hepcidin and their crosstalk as tumour-promoting signalling.
机构信息
Medical Oncology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford, 81, 00133, Rome, Italy.
PhD Program in Systems and Experimental Medicine (XXXV cycle), University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.
出版信息
Br J Cancer. 2023 Aug;129(2):222-236. doi: 10.1038/s41416-023-02266-2. Epub 2023 Apr 20.
Not all aspects of the disruption of iron homeostasis in cancer have been fully elucidated. Iron accumulation in cancer cells is frequent for many solid tumours, and this is often accompanied by the contemporary rise of two key iron regulators, HIF2α and Hepcidin. This scenario is different from what happens under physiological conditions, where Hepcidin parallels systemic iron concentrations while HIF2α levels are inversely associated to Hepcidin. The present review highlights the increasing body of evidence for the pro-tumoral effect of HIF2α and Hepcidin, discusses the possible imbalance in HIF2α, Hepcidin and iron homeostasis during cancer, and explores therapeutic options relying on these pathways as anticancer strategies.
并非癌症中铁稳态失调的所有方面都已完全阐明。许多实体瘤中癌细胞中铁的积累很常见，这通常伴随着两个关键的铁调节因子 HIF2α 和 Hepcidin 的同时升高。这种情况与生理条件下发生的情况不同，在生理条件下，Hepcidin 与全身铁浓度平行，而 HIF2α 水平与 Hepcidin 呈负相关。本综述强调了 HIF2α 和 Hepcidin 的促肿瘤作用的证据越来越多，讨论了癌症期间 HIF2α、Hepcidin 和铁稳态可能失衡的情况，并探讨了依赖这些途径作为抗癌策略的治疗选择。
Zotero 插件